22 §2694. Rulemaking
§2694. Rulemaking With the exception of rules designated in this subchapter as major substantive rules, rules adopted pursuant to this subchapter are routine technical rules as defined by Title 5, chapter 375, subchapter II‑A. [PL 1999, c. 786, Pt. A, §3 (NEW).] SECTION HISTORY PL 1999, c. 786, §A3 (NEW).
22 §2669. Penalties
§2669. Penalties The department may seek injunctive or other appropriative judicial relief for violations of any provisions of this chapter. [PL 1985, c. 150 (NEW).] SECTION HISTORY PL 1985, c. 150 (NEW).
22 §2697. Profiteering in prescription drugs
§2697. Profiteering in prescription drugs Prescription drugs are a necessity of life. Profiteering in prescription drugs is unlawful and is subject to the provisions of this section. The provisions of this section apply to manufacturers, distributors and labelers of prescription drugs. [PL 1999, c. 786, Pt. A, §3 (NEW).] 1. Definitions. As used in […]
22 §2671. Definitions
§2671. Definitions As used in this chapter, unless the context otherwise indicates, the following terms have the following meanings. [PL 2015, c. 418, §1 (NEW).] 1. Eligible patient. “Eligible patient” means a person who has: A. Received a diagnosis of a terminal illness for which no standard treatment is effective and the diagnosis […]
22 §2698. Investigation by Attorney General
§2698. Investigation by Attorney General The Attorney General, upon the Attorney General’s own initiative or upon petition of the commissioner or of 50 or more residents of the State, shall investigate suspected violations of this subchapter. [PL 1999, c. 786, Pt. A, §3 (NEW).] The Attorney General may require, by summons, the attendance and […]
22 §2672. Availability of investigational drug, biological product or device by manufacturer
§2672. Availability of investigational drug, biological product or device by manufacturer A manufacturer of an investigational drug, biological product or device may make available the investigational drug, biological product or device to an eligible patient. [PL 2015, c. 418, §1 (NEW).] 1. Compensation. A manufacturer may provide an investigational drug, biological product or device […]
22 §2673. Action against health care practitioner or health care provider license prohibited
§2673. Action against health care practitioner or health care provider license prohibited A licensing board may not revoke, refuse to renew or suspend the license of or take any action against a health care practitioner as defined in Title 24, section 2502, subsection 1-A based solely on the health care practitioner’s recommendations to an eligible […]
22 §2674. Officials, employees and agents of the State
§2674. Officials, employees and agents of the State 1. Violation. An official, employee or agent of the State may not block or attempt to block an eligible patient’s access to an investigational drug, biological product or device. [PL 2015, c. 418, §1 (NEW).] 2. Medical standards of care. This section does not prohibit an […]
22 §2675. No cause of action created
§2675. No cause of action created This chapter does not create a private cause of action against a manufacturer of an investigational drug, biological product or device or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product or device for any harm done to […]
22 §2676. Clinical trial coverage
§2676. Clinical trial coverage This chapter does not affect the mandatory health care coverage for participation in clinical trials pursuant to Title 24-A, section 4310. [PL 2015, c. 418, §1 (NEW).] SECTION HISTORY PL 2015, c. 418, §1 (NEW).